Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans

Aims To describe real-world use of esketamine (ESK) intranasal spray and healthcare outcomes among patients with treatment-resistant depression (TRD) in the United States (US). Methods Adults with TRD initiated on ESK (index date) between 5 March 2019 (US approval date for TRD) and 31 October 2020 were sampled from IBM MarketScan Research Databases. TRD was defined as claims for >= 2 unique antidepressants during the same major depressive episode. Subgroups of the TRD cohort with comorbid cardiometabolic conditions, pain, anxiety disorder, and substance use disorder (SUD) were identified. Patients had >= 6 months of continuous health plan eligibility pre- and post-index. Results The TRD cohort comprised 269 patients; comorbidity subgroups included 123 (cardiometabolic), 144 (pain), 189 (anxiety disorder), and 58 (SUD) patients. Proportion of patients completing >= 8 ESK sessions (number of sessions in induction phase) was 61.3% in the TRD cohort and ranged from 60.2% (cardiometabolic subgroup) to 72.4% (SUD subgroup) in subgroups. Median frequency of induction sessions was every 5-8 days among the TRD cohort and subgroups. Mean mental health-related inpatient costs reduced from pre- to post-index periods in the TRD cohort (mean +/- standard deviation [median] costs per-patient-per-6-months: $3,480 +/- $13,328 [$0] pre-ESK initiation; $3,262 +/- $16,666 [$0] post-ESK initiation; mean difference: -$218) and subgroups (largest decrease in cardiometabolic subgroup: $4,864 +/- $14,271 [$0]; $2,792 +/- $15,757 [$0]; -$2,072). Mean mental health-related emergency department (ED) costs decreased in the TRD cohort ($608 +/- $2,525 [$0]; $269 +/- $1,143 [$0]; -$339) and subgroups (largest decrease in the SUD subgroup: $1,403 +/- $3,752 [$0]; $351 +/- $868 [$0]; -$1,052). Limitations This is a descriptive analysis; sample size for some comorbidity subgroups is small. Conclusions The majority of patients completed ESK induction phase, and most dosing intervals were longer than the label recommendation. In this descriptive analysis, mental health-related inpatient and ED costs trended lower post-ESK initiation.

Automated summary

This study aimed to describe the real-world use of esketamine intranasal spray and healthcare outcomes among patients with treatment-resistant depression in the United States. The majority of patients completed the induction phase of esketamine treatment, and most dosing intervals were longer than recommended. Mental health-related inpatient and emergency department costs decreased after esketamine initiation.